A citation-based method for searching scientific literature

Luisa-Sophie Köster, Maren Carbon, Christoph U Correll. Expert Opin Emerg Drugs 2014
Times Cited: 32







List of co-cited articles
187 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.
Stefan Leucht, Andrea Cipriani, Loukia Spineli, Dimitris Mavridis, Deniz Orey, Franziska Richter, Myrto Samara, Corrado Barbui, Rolf R Engel, John R Geddes,[...]. Lancet 2013
21

The positive and negative syndrome scale (PANSS) for schizophrenia.
S R Kay, A Fiszbein, L A Opler. Schizophr Bull 1987
18

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.
Stefan Leucht, Caroline Corves, Dieter Arbter, Rolf R Engel, Chunbo Li, John M Davis. Lancet 2009
18

Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.
Kenji Maeda, Haruhiko Sugino, Hitomi Akazawa, Naoki Amada, Jun Shimada, Takashi Futamura, Hiroshi Yamashita, Nobuaki Ito, Robert D McQuade, Arne Mørk,[...]. J Pharmacol Exp Ther 2014
179
18


Past and present progress in the pharmacologic treatment of schizophrenia.
John M Kane, Christoph U Correll. J Clin Psychiatry 2010
163
15


Schizophrenia.
Jim van Os, Shitij Kapur. Lancet 2009
15

Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator.
Kenji Maeda, Linda Lerdrup, Haruhiko Sugino, Hitomi Akazawa, Naoki Amada, Robert D McQuade, Tine Bryan Stensbøl, Christoffer Bundgaard, Jørn Arnt, Tetsuro Kikuchi. J Pharmacol Exp Ther 2014
83
15


Second-generation antipsychotic effect on cognition in patients with schizophrenia--a meta-analysis of randomized clinical trials.
R E Nielsen, S Levander, G Kjaersdam Telléus, S O W Jensen, T Østergaard Christensen, S Leucht. Acta Psychiatr Scand 2015
155
15

Schizophrenia: a concise overview of incidence, prevalence, and mortality.
John McGrath, Sukanta Saha, David Chant, Joy Welham. Epidemiol Rev 2008
15

Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo.
Virginia L Stauffer, Brian A Millen, Scott Andersen, Bruce J Kinon, Lisa Lagrandeur, J P Lindenmayer, Juan Carlos Gomez. Schizophr Res 2013
77
12


The psychosis high-risk state: a comprehensive state-of-the-art review.
Paolo Fusar-Poli, Stefan Borgwardt, Andreas Bechdolf, Jean Addington, Anita Riecher-Rössler, Frauke Schultze-Lutter, Matcheri Keshavan, Stephen Wood, Stephan Ruhrmann, Larry J Seidman,[...]. JAMA Psychiatry 2013
881
12

11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).
Jari Tiihonen, Jouko Lönnqvist, Kristian Wahlbeck, Timo Klaukka, Leo Niskanen, Antti Tanskanen, Jari Haukka. Lancet 2009
769
12

Rethinking schizophrenia.
Thomas R Insel. Nature 2010
12


Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
Christoph U Correll, Peter Manu, Vladimir Olshanskiy, Barbara Napolitano, John M Kane, Anil K Malhotra. JAMA 2009
668
12

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
Marc De Hert, Johan Detraux, Ruud van Winkel, Weiping Yu, Christoph U Correll. Nat Rev Endocrinol 2011
597
12

EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors.
Jos Prickaerts, Nick P van Goethem, Richard Chesworth, Gideon Shapiro, Frank G Boess, Christoph Methfessel, Olga A H Reneerkens, Dorothy G Flood, Dana Hilt, Maria Gawryl,[...]. Neuropharmacology 2012
167
12

ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial.
Jeffrey A Lieberman, Robert E Davis, Christoph U Correll, Donald C Goff, John M Kane, Carol A Tamminga, Sharon Mates, Kimberly E Vanover. Biol Psychiatry 2016
41
12

Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission.
Gretchen L Snyder, Kimberly E Vanover, Hongwen Zhu, Diane B Miller, James P O'Callaghan, John Tomesch, Peng Li, Qiang Zhang, Vaishnav Krishnan, Joseph P Hendrick,[...]. Psychopharmacology (Berl) 2015
51
12

Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis.
Stefan Leucht, Magdolna Tardy, Katja Komossa, Stephan Heres, Werner Kissling, Georgia Salanti, John M Davis. Lancet 2012
464
12

Schizophrenia.
René S Kahn, Iris E Sommer, Robin M Murray, Andreas Meyer-Lindenberg, Daniel R Weinberger, Tyrone D Cannon, Michael O'Donovan, Christoph U Correll, John M Kane, Jim van Os,[...]. Nat Rev Dis Primers 2015
408
12

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia.
Stefan Leucht, Katja Komossa, Christine Rummel-Kluge, Caroline Corves, Heike Hunger, Franziska Schmid, Claudia Asenjo Lobos, Sandra Schwarz, John M Davis. Am J Psychiatry 2009
336
9

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Sandeep T Patil, Lu Zhang, Ferenc Martenyi, Stephen L Lowe, Kimberley A Jackson, Boris V Andreev, Alla S Avedisova, Leonid M Bardenstein, Issak Y Gurovich, Margarita A Morozova,[...]. Nat Med 2007
791
9

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Robert W Buchanan, Daniel C Javitt, Stephen R Marder, Nina R Schooler, James M Gold, Robert P McMahon, Uriel Heresco-Levy, William T Carpenter. Am J Psychiatry 2007
296
9

Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.
Kenji Hashimoto, Berend Malchow, Peter Falkai, Andrea Schmitt. Eur Arch Psychiatry Clin Neurosci 2013
162
9

Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
Hsien-Yuan Lane, Ching-Hua Lin, Michael F Green, Gerhard Hellemann, Chih-Chia Huang, Po-Wei Chen, Rene Tun, Yue-Cung Chang, Guochuan E Tsai. JAMA Psychiatry 2013
136
9


Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
Daniel Umbricht, Daniela Alberati, Meret Martin-Facklam, Edilio Borroni, Eriene A Youssef, Michael Ostland, Tanya L Wallace, Frédéric Knoflach, Ernest Dorflinger, Joseph G Wettstein,[...]. JAMA Psychiatry 2014
141
9


A systematic review and meta-analysis of recovery in schizophrenia.
Erika Jääskeläinen, Pauliina Juola, Noora Hirvonen, John J McGrath, Sukanta Saha, Matti Isohanni, Juha Veijola, Jouko Miettunen. Schizophr Bull 2013
400
9


Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.
Taishiro Kishimoto, Masahiro Nitta, Michael Borenstein, John M Kane, Christoph U Correll. J Clin Psychiatry 2013
299
9


Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.
Taishiro Kishimoto, Alfred Robenzadeh, Claudia Leucht, Stefan Leucht, Koichiro Watanabe, Masaru Mimura, Michael Borenstein, John M Kane, Christoph U Correll. Schizophr Bull 2014
264
9

What are we looking for in new antipsychotics?
Christoph U Correll. J Clin Psychiatry 2011
21
14

Almost all antipsychotics result in weight gain: a meta-analysis.
Maarten Bak, Annemarie Fransen, Jouke Janssen, Jim van Os, Marjan Drukker. PLoS One 2014
255
9

Antipsychotic drugs and obesity.
Christoph U Correll, Todd Lencz, Anil K Malhotra. Trends Mol Med 2011
190
9

Antipsychotic treatment and mortality in schizophrenia.
Minna Torniainen, Ellenor Mittendorfer-Rutz, Antti Tanskanen, Charlotte Björkenstam, Jaana Suvisaari, Kristina Alexanderson, Jari Tiihonen. Schizophr Bull 2015
119
9

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Jeffrey A Lieberman, T Scott Stroup, Joseph P McEvoy, Marvin S Swartz, Robert A Rosenheck, Diana O Perkins, Richard S E Keefe, Sonia M Davis, Clarence E Davis, Barry D Lebowitz,[...]. N Engl J Med 2005
9



Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
Béla Kiss, Attila Horváth, Zsolt Némethy, Eva Schmidt, István Laszlovszky, Gyula Bugovics, Károly Fazekas, Katalin Hornok, Szabolcs Orosz, István Gyertyán,[...]. J Pharmacol Exp Ther 2010
218
9

Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010.
Joshua A Salomon, Theo Vos, Daniel R Hogan, Michael Gagnon, Mohsen Naghavi, Ali Mokdad, Nazma Begum, Razibuzzaman Shah, Muhammad Karyana, Soewarta Kosen,[...]. Lancet 2012
802
9

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.
Theo Vos, Abraham D Flaxman, Mohsen Naghavi, Rafael Lozano, Catherine Michaud, Majid Ezzati, Kenji Shibuya, Joshua A Salomon, Safa Abdalla, Victor Aboyans,[...]. Lancet 2012
9

Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
Richard S E Keefe, Herbert A Meltzer, Nancy Dgetluck, Maria Gawryl, Gerhard Koenig, Hans J Moebius, Ilise Lombardo, Dana C Hilt. Neuropsychopharmacology 2015
92
9

ITI-007 demonstrates brain occupancy at serotonin 5-HT₂A and dopamine D₂ receptors and serotonin transporters using positron emission tomography in healthy volunteers.
Robert E Davis, Kimberly E Vanover, Yun Zhou, James R Brašić, Maria Guevara, Blanca Bisuna, Weiguo Ye, Vanessa Raymont, William Willis, Anil Kumar,[...]. Psychopharmacology (Berl) 2015
18
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.